PharmaGraphX

Log in Get Started

Erlotinib

Tarceva

Antineoplastic • EGFR tyrosine kinase inhibitor

Premium

HepatotoxicNephrotoxic

Half-life

36 hours

Protein Binding

95%

Metabolized By

CYP3A4, CYP1A2

External

Drugs.com

Clinical alerts

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Reversibly inhibits EGFR (HER1) tyrosine kinase

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Hereditary Leiomyomatosis and Renal Cell Carcinoma
·Papillary Renal Cell Carcinoma
·Renal Cell Carcinoma
·Sporadic Papillary Renal Cell Carcinoma
·Stage III Renal Cell Cancer AJCC v8

Interactions

No curated interaction pairs are recorded for Erlotinib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Rash
Diarrhea
Anorexia
Fatigue
Interstitial lung disease

Food, alcohol & herbal

Food

Take on empty stomach (food increases absorption variably)
Avoid grapefruit

Alcohol · moderate

May worsen hepatotoxicity

Herbal

St. John's Wort (major) — Reduces erlotinib levels

Pharmacokinetics

Half-life: 36 hours
Protein binding: 95%
Metabolised by: CYP3A4, CYP1A2

Pregnancy & lactation

Not recorded for Erlotinib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement